VivoSim Labs, Inc. (VIVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, VivoSim Labs, Inc. (VIVS) has a cash flow conversion efficiency ratio of -0.511x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.27 Million) by net assets ($4.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VivoSim Labs, Inc. net asset quality index to measure how much of total assets are equity-financed.
VivoSim Labs, Inc. - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how VivoSim Labs, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VivoSim Labs, Inc. (VIVS) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
VivoSim Labs, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VivoSim Labs, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Centaurus Energy Inc
V:CTA
|
-0.044x |
|
Black Spruce Exploration Inc.
V:BARK
|
-0.002x |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
-2.585x |
|
Insplorion AB
ST:INSP
|
-0.139x |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
-0.030x |
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
0.028x |
|
The Alumasc Group plc
LSE:ALU
|
0.068x |
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
0.082x |
Annual Cash Flow Conversion Efficiency for VivoSim Labs, Inc. (2011–2025)
The table below shows the annual cash flow conversion efficiency of VivoSim Labs, Inc. from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market value of VivoSim Labs, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $10.49 Million | $-9.46 Million | -0.902x | +77.84% |
| 2024-03-31 | $3.60 Million | $-14.65 Million | -4.069x | -402.71% |
| 2023-03-31 | $15.33 Million | $-12.41 Million | -0.809x | -189.28% |
| 2022-03-31 | $30.21 Million | $-8.45 Million | -0.280x | +17.68% |
| 2021-03-31 | $39.20 Million | $-13.32 Million | -0.340x | +39.17% |
| 2020-03-31 | $26.63 Million | $-14.88 Million | -0.559x | +0.45% |
| 2019-03-31 | $36.30 Million | $-20.38 Million | -0.561x | +13.27% |
| 2018-03-31 | $44.59 Million | $-28.86 Million | -0.647x | -38.30% |
| 2017-03-31 | $62.36 Million | $-29.18 Million | -0.468x | +0.91% |
| 2016-03-31 | $62.18 Million | $-29.37 Million | -0.472x | -17.34% |
| 2015-03-31 | $48.70 Million | $-19.60 Million | -0.403x | -24.90% |
| 2014-03-31 | $48.28 Million | $-15.56 Million | -0.322x | -117.63% |
| 2013-03-31 | $-5.30 Million | $-9.69 Million | 1.828x | -89.28% |
| 2011-03-31 | $-6.42K | $-109.42K | 17.052x | -- |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucida… Read more